I am a
Home I AM A Search Login

Papers of the Week


2021 May 03


J Am Acad Dermatol

Efficacy and Safety of Ruxolitinib Cream for the Treatment of Atopic Dermatitis: Results From Two Phase 3, Randomized, Double-Blind Studies.

Authors

Papp K, Szepietowski JC, Kircik L, Toth D, Eichenfield LF, Leung DYM, Forman SB, Venturanza ME, Sun K, Kuligowski ME, L Simpson E
J Am Acad Dermatol. 2021 May 03.
PMID: 33957195.

Abstract

Ruxolitinib (RUX) cream demonstrated potent anti-inflammatory and antipruritic efficacy in a phase 2 study in adults with atopic dermatitis (AD).